London – The University of Siena is in the international research team that identified a specific plasma markers profile in the response to the vaccine rVSV-ZEBOV, currently the only vaccine against Ebola with demonstrated efficacy in phase III clinical trials. The study was just published on the prestigious journal Science Translational Medicine, and took into account the plasma samples of healthy individuals vaccinated in Europe and Africa to identify a specific immune response and analyze the effects at different doses of the vaccine. (9colonne)
